BTOG 2019 | GioTag: real world data on first-line afatinib followed by osimertinb
The GioTag study aimed to assess outcomes of patients who received first-line afatinib followed by osimertinib in the real world. Here, Ken O’Byrne, MD, of the Princess Alexandra Hospital, Brisbane, Queensland, Australia, discusses the study, highlighting it’s importance in evaluating whether osimertinib should be used in the first-line setting. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland.
Get great new content delivered to your inboxSign up